The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison
Open accessPublished version of a preprint
Abstract
A central paradigm of immunity is that interferon (IFN)-mediated antiviral responses precede pro-inflammatory ones, optimizing host protection and minimizing collateral damage 1,2. Here, we report that for coronavirus disease 2019 (COVID-19) this paradigm does not apply. By investigating temporal IFN and inflammatory cytokine patterns in 32 moderate-to-severe patients with COVID-19 hospitalized for pneumonia and longitudinally followed for the development of respiratory failure and death, we reveal that IFN-λ and type I IFN production were both diminished and delayed, induced only in a fraction of patients as they became critically ill. On the contrary, pro-inflammatory cytokines such as tumor necrosis factor (TNF), interleukin (IL)-6 and IL-8 were produced before IFNs in all patients and persisted for a prolonged time. This condition was reflected in blood transcriptomes wherein prominent IFN signatures were only seen in critically ill patients who also exhibited augmented inflammation. By comparison, in 16 patients with influenza (flu) hospitalized for pneumonia with similar clinicopathological characteristics to those of COVID-19 and 24 nonhospitalized patients with flu with milder symptoms, IFN-λ and type I IFN were robustly induced earlier, at higher levels and independently of disease severity, whereas pro-inflammatory cytokines were only acutely produced. Notably, higher IFN-λ concentrations in patients with COVID-19 correlated with lower viral load in bronchial aspirates and faster viral clearance and a higher IFN-λ to type I IFN ratio correlated with improved outcome for critically ill patients. Moreover, altered cytokine patterns in patients with COVID-19 correlated with longer hospitalization and higher incidence of critical disease and mortality compared to flu. These data point to an untuned antiviral response in COVID-19, contributing to persistent viral presence, hyperinflammation and respiratory failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Impaired and delayed type I and type III IFN responses are associated with risk of severe COVID-19 (Galani et al., 2021; Hadjadj et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Galani et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Temporal dynamics in viral shedding and transmissibility of COVID-19
He, X., Lau, E. H. Y., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y. C., Wong, J. Y., Guan, Y., Tan, X., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0869-5 · Cited by 4,300
Cited by
Sorted by citations
Items 201–300 of 504
IL-27 expression regulation and its effects on adaptive immunity against viruses
Andres-Martin, F., James, C., & Catálfamo, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1395921 · Cited by 19
Evaluating the Immune Response in Treatment-Naive Hospitalised Patients With Influenza and COVID-19
Legebeke, J., Lord, J., Penrice-Randal, R., Vallejo, A. F., Poole, S., Brendish, N. J., Dong, X., Hartley, C. S., Holloway, J. W., Lucas, J. S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.853265 · Cited by 18
Kumar, R., Aktay-Cetin, Ö., Craddock, V. D., Morales‐Cano, D., Kosanovic, D., Cogolludo, A. L., Pérez‐Vizcaíno, F., Avdeev, S. N., Kumar, A., Ram, A. K., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011063 · Cited by 16
Insight into the mechanisms of coronaviruses evading host innate immunity
Yao, T., Foo, C., Zheng, G., Huang, R., Li, Q., Shen, J., & Wang, Z. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166671 · Cited by 18
Innate lymphoid cells (ILC) in SARS-CoV-2 infection
Kumar, A., Cao, W., Endrias, K., Kuchipudi, S. V., Mittal, S. K., & Sambhara, S. R. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101008 · Cited by 17
Impaired innate antiviral defenses in COVID-19: Causes, consequences and therapeutic opportunities
Galani, I. E., & Andreakos, E. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101522 · Cited by 17
Self-citationȚimpău, A. S., Miftode, R.-Ş., Leca, D. A., Timpau, R., Miftode, I.-L., Petriş, A. O., Costache, I. I., Mitu, O., Nicolae, A., Oancea, A. F., et al. (2022) · Life · doi:10.3390/life12071085 · Cited by 17
Grin, P. M., Baid, K., de Jesus, H. C. R., Kozarac, N., Bell, P. A., Jiang, S. Z., Kappelhoff, R., Butler, G. S., Leborgne, N. G. F., Pan, C. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115080 · Cited by 18
STINGing type I IFN-mediated immunopathology in COVID-19
Andreakos, E. (2022) · Nature Immunology · doi:10.1038/s41590-022-01174-6 · Cited by 16
Self-citationFungal Infections in Critically Ill COVID-19 Patients: Inevitabile Malum
Rovina, N., Koukaki, E., Romanou, V., Ampelioti, S., Loverdos, K., Chantziara, V., Koutsoukou, A., & Dimοpoulos, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11072017 · Cited by 17
Self-citationPacritinib Inhibition of IRAK1 Blocks Aberrant TLR8 Signalling by SARS-CoV-2 and HIV-1-Derived RNA
Campbell, G. R., Rawat, P., & Spector, S. A. (2022) · Journal of Innate Immunity · doi:10.1159/000525292 · Cited by 16
Wilder, C. L., Lefaudeux, D., Mathenge, R., Kishimoto, K., Munoz, A. Z., Nguyen, M. A., Meyer, A. S., Cheng, Q. J., & Hoffmann, A. (2023) · Molecular Systems Biology · doi:10.15252/msb.202211294 · Cited by 20
SARS-CoV-2 variant of concern fitness and adaptation in primary human airway epithelia
Meganck, R. M., Edwards, C. E., Mallory, M. L., Lee, R. E., Dang, H., Bailey, A. B., Wykoff, J. A., Gallant, S. C., Zhu, D. R., Yount, B. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114076 · Cited by 17
Smits, H. H., & Jochems, S. P. (2024) · European Respiratory Review · doi:10.1183/16000617.0266-2023 · Cited by 18
Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity
Wu, J., Liang, B.-Y., Fang, Y., Wang, H., Yang, X., Shěn, S., Chen, L., Li, S., Lu, S., Xiang, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722027 · Cited by 16
Pregnancy-specific responses to COVID-19 revealed by high-throughput proteomics of human plasma
Gomez‐Lopez, N., Romero, R. J., Escobar, M. F., Carvajal, J. A., Echavarría, M. P., Albornóz, L. L., Nasner, D., Miller, D., Gallo, D. M., Galaz, J., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00268-y · Cited by 17
Yadav, S., Fujimoto, K., Takenaga, T., Takahashi, S., Muramoto, Y., Mikawa, R., Noda, T., Gotoh, S., & Yokokawa, R. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01444-2 · Cited by 26
Lee, M.-C., Yu, C., Chen, X., Liu, M., Yang, J., Chen, A.-Y., & Huang, C.-H. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.998584 · Cited by 16
Time evolution of cytokine profiles associated with mortality in COVID-19 hospitalized patients
Prada, L. S.-D., Gorgojo-Galindo, Ó., Fierro, I., Martínez-García, A. M., de Quintana, G. S.-L., Bustillo, R. G., Pelaez-Jareño, M. T., Álvarez-Fuente, E., Gómez‐Sánchez, E., Tamayo, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.946730 · Cited by 14
Solanum nigrum L. in COVID-19 and post-COVID complications: a propitious candidate
Sharma, D., Joshi, M., Apparsundaram, S., Goyal, R. K., Patel, B. M., & Dhobi, M. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04654-3 · Cited by 18
Rasizadeh, R., Aghbash, P. S., Nahand, J. S., Entezari‐Maleki, T., & Baghi, H. B. (2023) · Virology Journal · doi:10.1186/s12985-023-02152-6 · Cited by 16
Immunology of SARS-CoV-2 infections and vaccines
Schenten, D., & Bhattacharya, D. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.002 · Cited by 14
Capelle, C., Ciré, S., Domingues, O., Ernens, I., Hedin, F., Fischer, A., Snoeck, C. J., Ammerlaan, W., Konstantinou, M., Grzyb, K., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100600 · Cited by 16
Myeloid dysregulation and therapeutic intervention in COVID-19
Gu, R., Mao, T., Qiao, L., Su, T. T., & Wang, J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101524 · Cited by 14
Kordyukova, L. V., & Shanko, A. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921070026 · Cited by 13
Sfikakis, P. P., Verrou, K., Tsitsilonis, O., Παρασκευής, Δ., Kastritis, E., Lianidou, E. S., Μουτσάτσου, Π., Terpos, E., Trougakos, I. P., Chini, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.746203 · Cited by 14
New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?
Rapti, V., Τσαγανός, Θ., Vathiotis, I. A., Syrigos, N. K., Li, P., & Poulakou, G. (2022) · Vaccines · doi:10.3390/vaccines10101607 · Cited by 16
Self-citationPuray‐Chavez, M., Eschbach, J. E., Xia, M., LaPak, K. M., Zhou, Q., Jasuja, R., Pan, J., Xu, J., Zhou, Z., Mohammed, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52803-7 · Cited by 14
Kelleni, M. T. (2021) · Immunologic Research · doi:10.1007/s12026-021-09219-y · Cited by 14
Liu, G., & Gack, M. U. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102252 · Cited by 14
Yuan, L., Zhu, H., Chen, P., Zhou, M., Ma, J., Liu, X. E., Wu, K., Chen, R., Liu, Q., Yu, H., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00923-9 · Cited by 14
Wu, W., Tian, L., Zhang, W., Booth, J. L., Ritchey, J. W., Wu, S., Xu, C., Brown, B. R., & Metcalf, J. P. (2022) · Scientific Reports · doi:10.1038/s41598-022-08066-7 · Cited by 14
He, X., Sun, Y., Lu, J., Naz, F., Ma, S., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117760 · Cited by 14
Antiviral response and immunopathogenesis of interleukin 27 in COVID-19
Valdés‐López, J. F., & Inchima, S. U. (2023) · Archives of Virology · doi:10.1007/s00705-023-05792-9 · Cited by 15
Bankoti, K., Wang, W., Amonkar, G. M., Xiong, L., Shui, J. E., Zhao, C., Van, E., Mwase, C., Park, J., Mou, H., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0104oc · Cited by 13
Immune responses in COVID-19 patients: Insights into cytokine storms and adaptive immunity kinetics
Zhang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34577 · Cited by 13
Identification of Immune Activation Markers in the Early Onset of COVID-19 Infection
Kovarik, J. J., Kaempf, A., Gasser, F., Herdina, A. N., Breuer, M., Kaltenecker, C. C., Wahrmann, M., Haindl, S., Mayer, F., Traby, L., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.651484 · Cited by 13
IFN-γ-mediated control of SARS-CoV-2 infection through nitric oxide
Silva, B. J. D. A., Krogstad, P. A., Teles, R. M. B., Andrade, P. R., Rajfer, J., Ferrini, M. G., Yang, O. O., Bloom, B. R., & Modlin, R. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1284148 · Cited by 15
Chronic Inflammation Might Protect Hemodialysis Patients From Severe COVID-19
Prietl, B., Odler, B., Kirsch, A. H., Artinger, K., Eigner, M., Schmaldienst, S., Pfeifer, V., Stanzer, S., Eberl, A., Raml, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.821818 · Cited by 12
A hydrated 2,3-diaminophenazinium chloride as a promising building block against SARS-CoV-2
Mahato, R. K., Mahanty, A. K., Kotakonda, M., Prasad, S., Bhattacharyya, S., & Biswas, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-02280-5 · Cited by 13
A benzimidazole scaffold as a promising inhibitor against SARS-CoV-2
Mudi, P. K., Mahanty, A. K., Kotakonda, M., Prasad, S., Bhattacharyya, S., & Biswas, B. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.2024448 · Cited by 13
Sposito, B., Broggi, A., Pandolfi, L., Crotta, S., Ferrarese, R., Sisti, S., Clementi, N., Ambrosi, A., Liu, E., Frangipane, V., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.30.437173 · Cited by 13
Interferon receptor gene dosage determines diverse hallmarks of Down syndromePreprint
Waugh, K. A., Minter, R., Baxter, J. A., Chi, C., Tuttle, K. D., Eduthan, N. P., Galbraith, M. D., Kinning, K. T., Andrysík, Z., Araya, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.03.478982 · Cited by 14
The endothelial-immunothrombotic storm in viral sepsis: lessons from COVID-19
Zhou, K., Chen, Y., Pang, J., Zhang, J., & Lu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1681764 · Cited by 16
Mechanisms of impairment of interferon production by SARS-CoV-2
Hoang, H., Naeli, P., Alain, T., & Jafarnejad, S. M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20221037 · Cited by 12
Okuma, N., Ito, M., Shimizu, T., Hasegawa, A., Ohmori, S., Yoshida, K., & Matsuoka, I. (2023) · Scientific Reports · doi:10.1038/s41598-023-48422-9 · Cited by 15
SIRT2 suppresses aging-associated cGAS activation and protects aged mice from severe COVID-19
Barthez, M., Xue, B., Zheng, J., Wang, Y., Song, Z., Mu, W., Wang, C.-L., Guo, J., Yang, F., Ma, Y., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115562 · Cited by 14
Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction
Ahmad, R., & Haque, M. (2022) · Vaccines · doi:10.3390/vaccines10040614 · Cited by 14
Jiménez, D., & Arias, M. T. (2022) · Immunological Medicine · doi:10.1080/25785826.2022.2066251 · Cited by 12
Tsioulos, G., Grigoropoulos, I., Moschopoulos, C. D., Shapira, S., Poulakou, G., Antoniadou, A., Boumpas, D. T., Arber, N., & Tsiodras, S. (2022) · Life · doi:10.3390/life12101472 · Cited by 12
Self-citationPredicting Influenza A Virus Infection in the Lung from Hematological Data with Machine Learning
Jhutty, S. S., Boehme, J. D., Jeron, A., Volckmar, J., Schultz, K., Schreiber, J., Schughart, K., Zhou, K., Steinheimer, J., Horst Stöcker, B., et al. (2022) · mSystems · doi:10.1128/msystems.00459-22 · Cited by 12
Kapten, K., Orczyk, K., & Smolewska, E. B. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00673-0 · Cited by 12
Ye, X.-L., Tian, S., Tang, C., Jiang, X., Liu, D., Yang, G., Zhang, H., Hu, Y., Li, T., Jiang, X., et al. (2023) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x23500532 · Cited by 12
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 12
Pezoulas, V. C., Kourou, K. D., Papaloukas, C. L., Triantafyllia, V., Lampropoulou, V., Siouti, E., Papadaki, M. E., Salagianni, M. L., Koukaki, E., Rovina, N., et al. (2021) · Diagnostics · doi:10.3390/diagnostics12010056 · Cited by 12
Self-citationCOVID-19: Are We Facing Secondary Pellagra Which Cannot Simply Be Cured by Vitamin B3?
Kujundžić, R. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084309 · Cited by 12
COVID-19 patients exhibit unique transcriptional signatures indicative of disease severity
Daamen, A. R., Bachali, P., Bonham, C. A., Somerville, L., Sturek, J. M., Grammer, A. C., Kadl, A., & Lipsky, P. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.989556 · Cited by 13
Shift of lung macrophage composition is associated with COVID-19 disease severity and recoveryPreprint
Chen, S. T., Park, M. D., Valle, D. M. D., Buckup, M., Tabachnikova, A., Simons, N. W., Mouskas, K., Lee, B. H., Geanon, D., D’souza, D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.11.475918 · Cited by 12
(Epi)transcriptomics in cardiovascular and neurological complications of COVID-19
Jusić, A., Stellos, K., Ferreira, L., Baker, A. H., & Devaux, Y. (2022) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2022.100013 · Cited by 10
Liu, Y., Li, Y., Xue, L., Xiao, J., Li, P., Xue, W., Li, C., Guo, H., & Chen, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1033982 · Cited by 10
Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19
Sidhu, J. K., Siggins, M. K., Liew, F., Russell, C. D., Uruchurtu, A. S. S., Davis, C., Turtle, L. C. W., Moore, S. C., Hardwick, H. E., Oosthuyzen, W., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad590 · Cited by 10
Infection‐induced inflammation from specific inborn errors of immunity to COVID‐19
Ku, C., Chen, I., & Lai, M. (2021) · FEBS Journal · doi:10.1111/febs.15961 · Cited by 11
Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19
Aricò, E., Bracci, L., Castiello, L., Urbani, F., Casanova, J., & Belardelli, F. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.12.001 · Cited by 11
Association of human myxovirus resistance protein A with severity of COVID-19
Lehtinen, O., Broman, N., Waris, M. E., Vuorinen, T., Peltola, V. T., Löyttyniemi, E., Oksi, J., & Feuth, T. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07753-0 · Cited by 11
Papanikolaou, C., Rapti, V., Stellas, D., Stefanou, D. T., Syrigos, K., Pavlakis, G. N., & Souliotis, V. L. (2022) · Vaccines · doi:10.3390/vaccines10101764 · Cited by 12
Self-citationWang, L., Guzman, M., Muñoz‐Santos, D., Honrubia, J. M., Ripoll-Gómez, J., Delgado, R. B., Sola, I., Enjuanes, L., & Zúñiga, S. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1268227 · Cited by 11
Abdalla, A. E., Xie, J., Junaid, K., Younas, S., Elsaman, T., Abosalif, K. O. A., Alameen, A. A. M., Mahjoob, M. O., Elamir, M. Y. M., & Ejaz, H. (2021) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2020.5543 · Cited by 11
Interferon-Lambda 1 Inhibits Staphylococcus aureus Colonization in Human Primary Keratinocytes
Wu, X., Zhao, Y. P., Gu, Y., Li, K., Wang, X., & Zhang, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.652302 · Cited by 11
IFNL3/4 polymorphisms as a two‐edged sword: An association with COVID‐19 outcome
Matić, S., Milovanović, D., Mijailović, Ž., Djurdjevic, P., Sazdanovic, P., Stefanovic, S., Todorović, D., Popović, S., Vitošević, K., Vukićević, V., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28506 · Cited by 7
Vanderbeke, L., Mol, P. V., Herck, Y. V., Smet, F. D., Humblet‐Baron, S., Martinod, K., Antoranz, A., Arijs, I., Boeckx, B., Bosisio, F. M., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3646561 · Cited by 11
Harnessing the power of IFN for therapeutic approaches to COVID-19
Viox, E. G., Bosinger, S. E., Douek, D. C., Schreiber, G., & Paiardini, M. (2024) · Journal of Virology · doi:10.1128/jvi.01204-23 · Cited by 12
Type III interferons in innate and adaptive immunity in the respiratory tract
Piperakis, A., Galani, I. E., & Andreakos, E. (2024) · Current Opinion in Immunology · doi:10.1016/j.coi.2024.102430 · Cited by 11
Self-citationXu, N., Pan, J., Li, S., Zhou, C., Huang, S., Chen, M., Zhang, J., Zhu, T., Li, J., Zhang, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.967716 · Cited by 11
Lu, J., Zeng, X., Lu, W., Feng, J., Yang, Y., Wei, Y., Chen, Y., Zhang, J., & Pinhu, L. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1207960 · Cited by 10
Nehar-Belaid, D., Mejías, A., Xu, Z., Marcheş, R., Yerrabelli, R., Guo, C., Mertz, S. E., Ye, F., Sánchez, P. J., Tsang, J. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59411-z · Cited by 9
Increase in Ischemia-Modified Albumin and Pregnancy-Associated Plasma Protein-A in COVID-19 Patients
Sánchez, B. G., Gasalla-Herraiz, J., Sánchez‐Chapado, M., Bort, A., & Díaz‐Laviada, I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235474 · Cited by 9
Coordinated regulation of interferon and inflammasome signaling pathways by SARS-CoV-2 proteins
Kim, N., & Song, Y. (2022) · The Journal of Microbiology · doi:10.1007/s12275-022-1502-8 · Cited by 9
Mallis, P., Chatzistamatiou, T. K., Dimou, Z., Sarri, E.-F., Georgiou, E., Salagianni, M. L., Triantafyllia, V., Andreakos, E., Stavropoulos‐Giokas, C., & Michalopoulos, Ε. (2022) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v13.i2.47 · Cited by 9
Self-citationAndreakos, E. (2024) · Seminars in Immunology · doi:10.1016/j.smim.2024.101863 · Cited by 12
Self-citationCirculating B10 regulatory cells are decreased in severe and critical COVID-19
Cervantes-Díaz, R., Sosa‐Hernández, V. A., Romero-Ramírez, S., Torres-Ruiz, J. J., Pérez-Fragoso, A., Meza-Sánchez, D. E., Gómez‐Martín, D., & Maravillas‐Montero, J. L. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.5covcra0721-387rr · Cited by 8
A virological view of tenascin-C in infection
Zuliani‐Alvarez, L., & Piccinini, A. M. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00333.2022 · Cited by 10
Bhargava, A., & Knapp, J. D. (2023) · Cells · doi:10.3390/cells12222591 · Cited by 9
Impaired activation of Transposable Elements in SARS-CoV-2 infectionPreprint
Sorek, M., Meshorer, E., & Schlesinger, S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.25.432821 · Cited by 9
Type I Interferon Autoantibodies Correlate With Cellular Immune Alterations in Severe COVID-19
Strunz, B., Maucourant, C., Mehta, A., Wan, H., Du, L., Sun, D., Chen, P., Nordlander, A., Gao, Y., Cornillet, M., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae036 · Cited by 8
Kattner, S., Müller, J., Glanz, K., Manoochehri, M., Sylvester, C., Vainshtein, Y., Berger, M. M., Brenner, T., & Sohn, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-30158-1 · Cited by 8
Häring, C., Jungwirth, J., Schroeder, J., Löffler, B., Engert, B., & Ehrhardt, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914584 · Cited by 8
Zhang, L., Nishi, H., & Kinoshita, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1194614 · Cited by 8
Yin and yang of interferons: lessons from the coronavirus disease 2019 (COVID-19) pandemic
Akusjärvi, S. S., & Zanoni, I. (2024) · Current Opinion in Immunology · doi:10.1016/j.coi.2024.102423 · Cited by 17
Aksu, M., van der Ent, T., Zhang, Z., Riza, A. L., de Nooijer, A., Ricaño-Ponce, I., Janssen, N. A. F., Engel, J. J., Streață, I., Dijkstra, H., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106300 · Cited by 8
Pan, T., Cao, G., Tang, E., Zhao, Y., Penaloza‐MacMaster, P., Fang, Y. H., & Huang, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1105673 · Cited by 10
Rizvi, Z. A., Madan, U., Tripathy, M. R., Goswami, S., Mani, S., Awasthi, A., & Dikshit, M. (2023) · Pharmaceuticals · doi:10.3390/ph16091333 · Cited by 8
Credle, J. J., Gunn, J., Sangkhapreecha, P., Monaco, D. R., Zheng, X. A., Tsai, H.-J., Wilbon, A., Morgenlander, W. R., Dong, Y. W., Jayaraman, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.02.432977 · Cited by 8
Ageing impairs the airway epithelium defence response to SARS-CoV-2Preprint
Capraro, A., Wong, S. L., Adhikari, A., Allan, K. M., Patel, H. R., Zhong, L., Raftery, M. J., Jaffé, A., Yeang, M., Aggarwal, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.05.437453 · Cited by 9
Venet, M., Ribeiro, M. S., Décembre, É., Bellomo, A., Joshi, G., Villard, M., Cluet, D., Perret, M., Pescamona, R., Païdassi, H., et al. (2021) · medRxiv · doi:10.1101/2021.09.01.21262969 · Cited by 8
PRRSV NSP5 orchestrates dual immune disruption by targeting NLRP3 and STING
Huang, X., Xiang, X., Jiang, X., Qu, W., Zhang, Y., Zhao, Z., Li, M., Wang, H., & Li, X. (2025) · Veterinary Research · doi:10.1186/s13567-025-01636-3 · Cited by 9
Saikh, K. U., Anam, K., Sultana, H., Ahmed, R., Kumar, S., Srinivasan, S., & Ahmed, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158421 · Cited by 7
Cha, H., Lee, C. M., Kim, S., Kang, C. K., Choe, P. G., Jeon, Y. K., Jo, H. J., Kim, N. J., Park, W. B., & Kim, H. J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05401-1 · Cited by 7
Expression and function of interferon lambda receptor 1 variants
Novotny, L. A., & Meissner, E. G. (2024) · FEBS Letters · doi:10.1002/1873-3468.15041 · Cited by 9
Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine
Russick, J., Foy, P.-E., Josseaume, N., Meylan, M., Benhamouda, N., Kirilovsky, A., Sissy, C. E., Tartour, É., Smadja, D. M., Karras, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701273 · Cited by 7
Ackerman, E. E., Weaver, J. J. A., & Shoemaker, J. E. (2022) · Viruses · doi:10.3390/v14050906 · Cited by 8
Metadata
- Authors
- Galani, I.-E., Rovina, N., Lampropoulou, V., Triantafyllia, V., Manioudaki, M., Pavlos, E., Koukaki, E., Fragkou, P. C., Panou, V., Rapti, V., Koltsida, O., Mentis, A., Koulouris, N., Tsiodras, S., Koutsoukou, A., & Andreakos, E.
- Affiliations
- Biomedical Research Foundation of the Academy of Athens (GR)
- National and Kapodistrian University of Athens (GR)
- Sotiria General Hospital (GR)
- Pasteur Hellenic Institute (GR)
- Corresponding author
- Andreakos, Evangelos
- ORCID
- Venue
- Nature Immunology
- Published
- 2020-12-04
- Volume
- 22
- Issue
- 1
- Pages
- 32-40
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W3107596380
- Cited by
- 503
- References
- 41
- Citations by year
- 2026: 22 · 2025: 46 · 2024: 58 · 2023: 91 · 2022: 156 · 2021: 128 · 2020: 1
- FWCI
- 32.87
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature Immunology (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed (publishedVersion)
- Funders
- EC | Horizon 2020 Framework Programme (779295, 767015)
- Janssen Pharmaceuticals
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- COVID-19 pandemic, SARS-CoV-2, influenza, type I interferon, interferon lambda, antiviral immunity, inflammatory cytokines, interleukin-6, TNF-α, interleukin-8, hyperinflammation, viral load, viral clearance, respiratory failure, mortality, blood transcriptome, cytokine dynamics
- MeSH terms
- COVID-19, SARS-CoV-2, Interferon Lambda, Humans, Immunity, Inflammation, Influenza, Human, Interferon Type I, Interferons, Length of Stay, Prognosis, Gene Expression, Cytokines, Disease Progression, Viral Load, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
